ArticleNature immunology2022
Immune signature atlas of vaccines: learning from the good responders.
Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults.Nature communications · 2026Trial
- High-dimensional profiling following third MMR vaccination or mumps virus infection reveals individuals with suboptimal immunity.Communications medicine · 2026Article
- A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.Nature immunology · 2026Article
- Pre-Vaccination Immunotypes and Immune Entropy Are Indicators of Multiple Vaccine Responsiveness.Aging cell · 2025Article
- A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity.Frontiers in immunology · 2025Article
- Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity.Human vaccines & immunotherapeutics · 2023Review
- An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines.Journal of pharmaceutical sciences · 2023Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.